Get started
Author

Mary Anne Quintayo

Observed names: M A Quintayo, M. A. Quintayo, M. Quintayo, Mary-Anne Quintayo
Observed institutions: Ontario Institute for Cancer Research, University of Toronto, Western General Hospital, Edinburgh Cancer Research, MaRS, University of Edinburgh
ORCID: 0009-0005-7753-2261
Observed ORCID: 0009-0005-7753-2261
OpenAlex ID: A5024568534
GSK3β and cyclin D1 expression predicts outcome in early breast cancer patients
2012 · Mary Anne Quintayo, Alison F. Munro, et al. · Breast Cancer Research and Treatment · 59
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study
2022 · Balazs Acs, Samuel C.Y. Leung, et al. · Modern Pathology · 48
PDF
Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine
2017 · Jane Bayani, Cindy Q. Yao, et al. · npj Breast Cancer · 28
PDF
The p160 ER co-regulators predict outcome in ER negative breast cancer
2011 · Melanie Spears, Steffi Oesterreich, et al. · Breast Cancer Research and Treatment · 17
Intra-tumoral spatial heterogeneity in breast cancer quantified using high-dimensional protein multiplexing and single cell phenotyping
2025 · Alison M. Cheung, Dan Wang, et al. · Breast Cancer Research · 14
PDF
Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial
2017 · Antonia K Roseweir, Lindsay Bennett, et al. · JNCI Journal of the National Cancer Institute · 13
Virtual tissue microarrays: a novel and viable approach to optimizing tissue microarrays for biomarker research applied to ductal carcinoma in situ
2013 · Mary Anne Quintayo, Jane Starczynski, et al. · Histopathology · 10
Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial
2013 · J M S Bartlett, C L Brookes, et al. · British Journal of Cancer · 10
PDF
TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial
2015 · on behalf of the NCIC CTG, J M S Bartlett, et al. · British Journal of Cancer · 7
PDF
The TEAM Trial Pathology Study Identifies Potential Prognostic and Predictive Biomarker Models for Postmenopausal Patients Treated with Endocrine Therapy.
2009 · J. Bartlett, C. Brookes, et al. · Cancer Research · 5
Expression of activated type I receptor tyrosine kinases in early breast cancer
2012 · Melanie Spears, Hans Christian Pederson, et al. · Breast Cancer Research and Treatment · 4
Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole
2024 · Judith-Anne W. Chapman, Jane Bayani, et al. · Journal of Clinical Oncology · 3
PDF
Heterogeneity and immune microenvironment of early invasive estrogen receptor-positive breast cancer reveal an immune-rich subset
2026 · Drashti Jain, Linda Liao, et al. · npj Breast Cancer · 2
PDF
Abstract 3131: Tumour spatial heterogeneity in breast cancer and the impact on clinical management
2021 · Jane Bayani, Quang M. Trinh, et al. · Cancer Research · 1
Abstract P5-02-01: Analytical validation and prognostic potential of an automated digital scoring protocol for Ki67: An International Ki67 Working Group study
2020 · Balazs Acs, Samuel C.Y. Leung, et al. · Cancer Research · 1
Estrogen-Driven Breast Carcinogenesis in a Rat Model is Linked to Retroelement Activation and Inflammation and is Susceptible to Lamivudine Treatment
2026 · Valentina Evdokimova, Zhenbo Zhang, et al. · Breast Cancer Targets and Therapy
Impact of Genomic Mutations on the Transcriptional Pathways and Tumor Microenvironment Landscape of Localized Early Prostate Cancer
2026 · William Lautert‐Dutra, Camila M. Melo, et al. · The Prostate
Abstract PS3-07-23: Survivor plots for quantitated adjunctive statistically standardized ER, PgR, and HER2 in adjuvant postmenopausal breast cancer: Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole
2026 · J. W. Chapman, J. Bayani, et al. · Clinical Cancer Research
Adjunctive statistical standardization of quantitated adjuvant HER2 and ultra-low HER2 in Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole
2025 · Judith-Anne W. Chapman, Jane Bayani, et al. · Breast Cancer Research and Treatment
PDF
Abstract P1-07-06: Adjunctive statistical standardization of quantitated adjuvant HER2 and very low statistically standardized HER2 in CCTG MA.27
2025 · Judith-Anne Chapman, Jane Bayani, et al. · Clinical Cancer Research
Adjunctive statistical standardization of quantitated adjuvant ER and PgR in CCTG MA.27.
2024 · Judy-Anne Williams Chapman, Jane Bayani, et al. · Journal of Clinical Oncology
Abstract PO1-27-10: Adjunctive statistical standardization of quantitated machine image analysis of Estrogen and Progesterone Receptors: CCTG MA.27 trial
2024 · Judy-Anne Chapman, Jane Bayani, et al. · Cancer Research
Abstract 5548: Clinical management and decision making in early ER-positive breast cancers through improved prognosis and pathway directed molecular profiling
2023 · John M. Bartlett, Cheryl Crozier, et al. · Cancer Research
Abstract 2698: Spatial gene expression profiling in breast cancer
2021 · Melanie Spears, Vida Talebian, et al. · Cancer Research
Abstract 2726: Characterization of immune microenvironment and heterogeneity in breast cancer subtypes
2021 · Drashti Jain, Linda Liao, et al. · Cancer Research
Works count: 33
Citation count: 270
H-index: 9
I10-index: 9
Year
Topic
Type